CoreCivic Reports Third Quarter 2026 Financial Results
CoreCivic reported Q3 2026 net income of $1.34B ($14.49 EPS), up from $26.3M ($0.24 EPS) in Q3 2025, driven by facility activations and acquisitions. Adjusted net income was $45.7M ($0.49 EPS). CEO transition occurred due to health reasons. Federal customers contributed 53% of revenue. EBITDA rose to $1.90B, with Adjusted EBITDA up 32.6%. Facility sales totaled $2.2B.
How this was made

The 30-second read
Why it matters
The earnings beat and occupancy gains are likely to drive short-term price appreciation, though the exec change adds some risk.
Market read
Strong earnings and occupancy growth provide a catalyst for CXW, with potential spillover to the sector.
What to watch
One-time gains from real estate sales may not be repeatable.
Background
CoreCivic disclosed its Q3 2026 financials, highlighting a leadership transition and acquisition of Clinical Solutions Pharmacy.
Ticker impact
CoreCivic reported Q3 2026 results with net income of $1.34B, EPS $14.49, and strong occupancy growth.
potential upside as market prices in higher earnings and occupancy growth
The surprise magnitude of earnings and guidance on new facilities indicate material improvement.
Market effects
Private prison sector may see renewed investor interest from earnings beat.
U.S. correctional services stocks could experience correlated moves.
Limited to U.S. listed correctional services firms.
Counterpoint
Exec turnover and debt repayments could weigh on near-term sentiment.
Key entities
- CompanyCoreCivic
U.S.-listed correctional services provider.



